TruScreen Seeks UNITAID Backing for Global Cervical Cancer Screening Push

TruScreen Group Ltd. ( (AU:TRU) ) just unveiled an update.

TruScreen Group has submitted three major funding proposals to UNITAID to deploy its AI-enabled cervical screening technology across 14 high-burden countries in Africa, Asia-Pacific, and Latin America, covering an addressable market of about one billion women. The programmes, with potential funding of up to US$57.3 million and up to US$18.4 million in revenue for TruScreen as consortium lead, aim to scale device deployment, train health workers, and significantly expand screening in underserved peri-urban and rural settings.

Two proposals focus on Sub-Saharan Africa, including a 36‑month scale-up across six countries and a transformative same-visit screen‑and‑treat model combining HPV rapid testing with TruScreen examinations to close the gap between diagnosis and treatment. A third proposal targets eight countries in Asia-Pacific and Latin America to convert existing pilots and regulatory footholds into nationally funded screening programmes, positioning TruScreen as a core component of national cervical cancer strategies and deepening its partnerships with NGOs and health ministries.

More about TruScreen Group Ltd.

TruScreen Group Ltd. is a medical technology company focused on cervical cancer screening, offering a portable, AI-enabled opto-electronic device designed for point-of-care use without the need for laboratories or pathologists. Its technology targets low- and middle-income countries, where screening coverage is low and healthcare infrastructure is limited, and is already approved and in use across multiple markets including China, Vietnam, and Zimbabwe.

For an in-depth examination of TRU stock, go to TipRanks’ Overview page.